Login / Signup

Efficacy of Infliximab Dose Escalation in Patients with Refractory Immunotherapy-Related Colitis: A Case Series.

Jessica P HarrisMichael A PostowDavid M Faleck
Published in: The oncologist (2022)
Immune checkpoint inhibitor-related colitis is a common complication of immunotherapy use in patients with cancer. Current guidelines recommend treatment with standard dose infliximab (IFX) for corticosteroid-refractory colitis; however, this case series suggests IFX dose escalation may be a viable treatment option for refractory cases.
Keyphrases
  • ulcerative colitis
  • clinical trial
  • randomized controlled trial
  • clinical practice
  • study protocol